Ritu Baral
Stock Analyst at TD Cowen
(0.78)
# 3,692
Out of 4,784 analysts
38
Total ratings
33.33%
Success rate
-18.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $44 | $28.10 | +56.58% | 1 | Feb 5, 2025 | |
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $9 | $8.28 | +8.70% | 6 | Nov 21, 2024 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $0.77 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.39 | - | 2 | Nov 18, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $56 → $78 | $31.60 | +146.84% | 1 | Oct 21, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $268.46 | +38.20% | 4 | Oct 21, 2024 | |
| INSM Insmed | Maintains: Buy | $75 → $98 | $77.99 | +25.66% | 3 | Aug 9, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $349 → $390 | $327.87 | +18.95% | 1 | Mar 15, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $3.71 | - | 1 | Aug 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $70.41 | +148.54% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $21 | $17.07 | +23.02% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.30 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.64 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.06 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.47 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $26.63 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.92 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.47 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.71 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $534.95 | - | 2 | Jan 12, 2018 |
Palvella Therapeutics
Feb 5, 2025
Initiates: Buy
Price Target: $44
Current: $28.10
Upside: +56.58%
Sage Therapeutics
Nov 21, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $8.28
Upside: +8.70%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.77
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.39
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56 → $78
Current: $31.60
Upside: +146.84%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $268.46
Upside: +38.20%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75 → $98
Current: $77.99
Upside: +25.66%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349 → $390
Current: $327.87
Upside: +18.95%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.71
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $70.41
Upside: +148.54%
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $17.07
Upside: +23.02%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $0.30
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.64
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.06
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.47
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $26.63
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.92
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.47
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.71
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $534.95
Upside: -